The Office of Generic Drugs (OGD) updated its Report of the Generic Drugs Program for May to add some additional figures. While there are no real surprises, it is notable to point out that the number of changes being effected (CBE) supplements soared to almost 700 (690), which is by far the largest number of […]
The Office of Generic Drugs (OGD) has issued a revised Manual of Policies and Procedures (MaPP) updating the new organizational structure and defining where in the CDER and FDA organization reviews of bioequivalence studies with clinical endpoints will be conducted. The MaPP, 5210.4, Rev. 2, makes one thing clear, and that is that the initial […]
The FDA has published guidance for the submission of facility information that is required to assure the shorter review timeframe for priority submissions. This is a new provision of the GDUFA II negotiation and appears in the Commitment Letter. This pre-submission must be into OGD 2 months prior to submission of the priority application, supplement, […]
The Congressional Budget Office (CBO) has scored (costed out) additional costs for the provisions of GDUFA II reauthorization over and above the $493.6 million/year (GDUFA II first year fee collection). The CBO speaks about the additional costs for the new amendments added to GDUFA II, which are believed to be over the fee collection under […]
On May 16, 2017, we published a blog post on the issue of new and revised bioequivalence (BE) guidances (here) and the impact on industry relative to the potential to have to repeat studies that have already been conducted for pending application or developed products where the ANDA has not yet been submitted. There is […]
The month of May 2017 may go down as the true turning point in the Office of Generic Drugs (OGD) review and approval process. If not, it will at least go down as the second highest number of approval actions in a single month since the start of the GDUFA program. OGD reported fully approving […]
In what (I believe) is only the second opioid that FDA is seeking to remove from the market because the risk no longer outweighs the benefits of the product (first was the original formulation of Oxycontin), the Agency said “After careful consideration, the agency is seeking removal based on its concern that the benefits of […]
After slogging through some of the FDA dashboards, I came across one that I felt was worthy of mention. The FDA’s Office of Regulatory Affairs (ORA) has apparently begun the process of scoring drug manufacturing establishments in their risk-based inspection program. The FDA has been talking about risk-based inspection (as well as risk-based review) ever […]
As reported by FDA WebView (here [subscription required]), FDA announced the appointment of three former congressional staffers Dr. Gottlieb has chosen to add to his current team, as his team builds his vision for the Agency is becoming more clear. And it is not the usual vision we have seen from past commissioners. As an example, […]
Despite great efforts by the FDA and the industry, there still are 55 different drug products under shortage on the FDA’s list (here). While the number of drugs on the shortage list is much lower than we have seen in the past (100+), there is still cause for concern as products move on and off […]
